Data Dictionary: Pancreatic cancer - DPCA: Difference between revisions

From Beacon
No edit summary
No edit summary
Line 84: Line 84:




**SARS-CoV-2 Suspected or Confirmed Infection**
'''SARS-CoV-2 Suspected or Confirmed Infection'''
* Presence of a clinical suspicion or test for SARS-CoV-2 infection prior to and up to 30 days post-admission.
* Presence of a clinical suspicion or test for SARS-CoV-2 infection prior to and up to 30 days post-admission.
* Date of the first suspicion of SARS-CoV-2 infection.
* Date of the first suspicion of SARS-CoV-2 infection.
Line 92: Line 92:




**Preoperative and Postoperative COVID-19 Testing**
'''Preoperative and Postoperative COVID-19 Testing'''
* Number of preoperative RT-PCR tests and the date of the first test.
* Number of preoperative RT-PCR tests and the date of the first test.
* Date of the first preoperative CT thorax with COVID-19 concern and CORADS 4-5 score.
* Date of the first preoperative CT thorax with COVID-19 concern and CORADS 4-5 score.
Line 100: Line 100:




**Patient Characteristics**
'''Patient Characteristics'''
* Symptoms indicative of COVID-19 (e.g., cough, fever, dyspnea, loss of smell/taste).
* Symptoms indicative of COVID-19 (e.g., cough, fever, dyspnea, loss of smell/taste).
* Patient's smoking status and pack-years.
* Patient's smoking status and pack-years.
Line 106: Line 106:




**Surgical and Intensive Care Considerations**
'''Surgical and Intensive Care Considerations'''
* Presence of preoperative COVID-19 related complications (e.g., ARDS, acute renal failure, arrhythmias, thromboembolic events).
* Presence of preoperative COVID-19 related complications (e.g., ARDS, acute renal failure, arrhythmias, thromboembolic events).
* Impact on neoadjuvant treatment and changes in treatment plans or schedules.
* Impact on neoadjuvant treatment and changes in treatment plans or schedules.
Line 113: Line 113:




**ICU Admission Related to COVID-19**
'''ICU Admission Related to COVID-19'''
* Presence and type of ICU admission related to COVID-19.
* Presence and type of ICU admission related to COVID-19.
* Type of respiratory support during ICU stay (e.g., prone ventilation, ECMO).
* Type of respiratory support during ICU stay (e.g., prone ventilation, ECMO).
* ICU admission and discharge dates and durations.
* ICU admission and discharge dates and durations.
* Destination after ICU discharge.
* Destination after ICU discharge.

Revision as of 21:34, 8 May 2024

Go back to Dutch Institute for Clinical Auditing Databases (DICA) (The Netherlands) page.

This is a summary of the variables available in the database. You can download the complete data dictionary. [Click here to learn more.

Patient Demographics and Identification:

  • Healthcare Institution (Zorginstelling)
  • Unique Patient Number (Uniek Patiëntnummer)
  • Social Security Number (Burger Service Nummer)
  • Surname (Geslachtsnaam)
  • Date of Birth (Geboortedatum)
  • Gender (Geslacht)
  • Country (Country of Residence) (Land (Woonadres))
  • Postal Code (Postcode)
  • Date of Death (if applicable) (Datum overlijden (indien van toepassing))


Comorbidities:

  • Comorbidities, with options to add a new record or update based on changes or previous registrations (Comorbiditeiten)


Medical Procedures:

  • Procedures, where multiple procedures per patient can be registered if applicable (Verrichtingen)


COVID-19 Module:

  • A generic COVID-19 module added due to the impact of the coronavirus crisis on the quality of care, allowing for the better interpretation of indicators during this period (Deze generieke COVID-19 module)


Pathology Variables through PALGA:

  • Pathology variables automatically structured and included in the registration via the PALGA-pathology module, requiring no additional data (In het kader van de PALGA-koppeling worden pathologie variabelen)


Patient Identification and Treatment Timeline

  • Treatment start date
  • Reason for registration
  • Hospital patient number


Patient Physical and Performance Metrics

  • Height in cm
  • Preoperative weight in kg
  • Weight loss in kg and period in weeks
  • ECOG performance status (Eastern Cooperative Oncology Group)


Laboratory Biomarkers

  • Bilirubine in µmol/l
  • Hemoglobine in mmol/l
  • Albumine in g/l
  • IgG4 in g/l
  • Carcinoembryonic antigen (CEA) in µg/l
  • CA19.9 in kU/l (Note: Last CA19.9 before the start of neoadjuvant treatment or surgery)


Imaging and Diagnostic Procedures

  • CT, MRI, or MRCP performed
  • Date of the last preoperative imaging
  • Presence of a tumor in the pancreas or periampullary on CT or MRI
  • Cystic features suggestive of malignancy
  • Involvement of vessels and other structures on imaging


Histology and Cytology

  • Preoperative PA number
  • Method and date of obtaining the first positive cytology or histology
  • Histological and cytological diagnoses


Multidisciplinary Team Consultations and Decisions

  • Date of the last MDT (Multidisciplinary Team) discussion before treatment
  • Working diagnosis and eligibility for surgical exploration


Treatment and Surgery Details

  • Neo-adjuvant/induction treatment type and start date
  • Operative details including ASA score, type of resection, and operative complications
  • Postoperative pathology including tumor origin, size, and grade


Postoperative Management and Follow-Up

  • Palliative treatments including chemotherapy and radiotherapy
  • Date of discharge and any readmissions within 30 days
  • Adjuvant therapy details and participation in oncological trials


SARS-CoV-2 Suspected or Confirmed Infection

  • Presence of a clinical suspicion or test for SARS-CoV-2 infection prior to and up to 30 days post-admission.
  • Date of the first suspicion of SARS-CoV-2 infection.
  • Date of the first specific test for SARS-CoV-2 infection.
  • Date of the first positive laboratory test for SARS-CoV-2.
  • Final status regarding SARS-CoV-2 infection.


Preoperative and Postoperative COVID-19 Testing

  • Number of preoperative RT-PCR tests and the date of the first test.
  • Date of the first preoperative CT thorax with COVID-19 concern and CORADS 4-5 score.
  • Number of postoperative RT-PCR tests and the date of the first test.
  • Date of the first postoperative CT thorax with COVID-19 concern and CORADS 4-5 score.
  • Definitive preoperative and postoperative COVID-19 status.


Patient Characteristics

  • Symptoms indicative of COVID-19 (e.g., cough, fever, dyspnea, loss of smell/taste).
  • Patient's smoking status and pack-years.
  • Patient's height (in cm) and weight (in kg) at admission.


Surgical and Intensive Care Considerations

  • Presence of preoperative COVID-19 related complications (e.g., ARDS, acute renal failure, arrhythmias, thromboembolic events).
  • Impact on neoadjuvant treatment and changes in treatment plans or schedules.
  • Impact on surgical approach (laparoscopic, robotic, open) due to COVID-19.
  • Postoperative complaints consistent with COVID-19 and the number of days post-surgery they began.


ICU Admission Related to COVID-19

  • Presence and type of ICU admission related to COVID-19.
  • Type of respiratory support during ICU stay (e.g., prone ventilation, ECMO).
  • ICU admission and discharge dates and durations.
  • Destination after ICU discharge.